Background In adults with heart failure, elevated levels of fibroblast growth factor 23 (FGF23) are associated with mortality. Data on FGF23 levels in pediatric heart failure are lacking. Patients and methods We conducted a cross-sectional study of 17 healthy children (mean age 13 years) and 20 pediatric patients with heart failure (mean age 12 years) who underwent echocardiography and for whom the following measurements were taken: plasma FGF23 and parathyroid hormone (PTH) and serum phosphate, creatinine and N-terminal prohormone brain natriuretic peptide (NT-proBNP). Symptom severity was assessed with the New York Heart Association and the Ross classification systems. Results Of the 20 patients, 11 had dilated cardiomyopathy, four had congenital heart disease, three had hypertrophic cardiomyopathy, one had a failing heart transplant and one had pulmonary hypertension. Mean phosphate levels in these patients were within the reported reference range for healthy children. Median PTH levels were in the normal range in patients and controls. The median FGF23 level was higher in patients versus controls (110.9 vs. 66.4 RU/ml; P=0.03) and higher in patients on diuretics versus other patients (222.4 vs. 82.1 RU/ml; P=0.01). Levels of FGF23 and NT-proBNP were directly correlated (r=0.47, P=0.04), and patients with greater physical functional impairment had higher FGF23 levels (142.5 in those with moderate-severe limitation vs. 92.8 RU/ml in those with no limitation; P=0.05). Among patients with dilated cardiomyopathy, higher FGF23 levels were associated with a greater left ventricular end-diastolic diameter (r=0.63, P=0.04). Conclusion FGF23 levels are elevated in children with heart failure and are associated with diuretic use, severity of heart failure and left ventricular dilation.
Introduction
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates mineral metabolism by promoting phosphaturia and decreasing renal production of calcitriol [1] . Dietary phosphate loading increases FGF23 levels, whereas dietary phosphate restriction has the opposite effect [2] [3] [4] . Levels of FGF23 are frequently elevated in patients with chronic kidney disease (CKD) [5] . In this setting of progressive loss of kidney function, the physiologic actions of FGF23 initially maintain normophosphatemia at the expense of calcitriol deficiency [6] , but over time the levels become markedly elevated, with the highest FGF23 levels observed in patients without residual renal function and who are undergoing dialysis [7] .
Given the prevalence of elevated FGF23 levels in kidney disease, there has been significant scientific interest in the potential systemic effects of FGF23. Observational studies first suggested this possibility by reporting that elevated FGF23 levels were associated with increased risks of cardiovascular disease events and mortality in the general population and across the spectrum of CKD [8] [9] [10] [11] . An independent association between left ventricular (LV) hypertrophy and FGF23 levels [12] [13] [14] led to the hypothesis that FGF23-mediated LV remodeling might be one putative mechanism for the consistently reported risk relationships. In support of this framework, serum levels of cardiac troponins and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were found to correlate directly with FGF23 in various study populations, including patients with heart failure and/or CKD and those undergoing dialysis [15] [16] [17] [18] . Recently, experimental studies have provided additional evidence for increased FGF23 as a potential mechanism for LV hypertrophy [19] .
To date, two studies in the adult heart failure population have evaluated FGF23 levels as a predictor of death [15, 16] . Comparable data in children with heart failure are not available. Therefore, we investigated FGF23 levels among pediatric heart failure patients, compared these with levels in healthy controls and evaluated the relationship of FGF23 with symptom severity, NT-proBNP and echocardiographic measures.
Patients and methods

Study population
From June to December 2011, we studied 20 patients at the University of Miami/Jackson Memorial Hospital Pediatric Heart Failure and Transplant Clinic. All consecutive patients, aged up to 21 years, were enrolled; there were no exclusion criteria. All patients had a diagnosis of heart failure, as defined by the International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children [20] . Additionally, we assayed stored blood specimens from 17 healthy children, who were frequency-matched on age, gender, race and ethnicity, and these measurements were used as convenience sample controls. These healthy children were controls in a previously published case-control study of biomarkers of vascular dysfunction in human immunodeficiency virusinfected children [21] . Briefly, the controls did not have any chronic illness or acute infectious process and were from similar geographic and socioeconomic backgrounds as the children with heart failure. The University of Miami Institutional Review Board approved the study, and informed consent from the parent or guardian and assent from the patient (when appropriate) were obtained.
Demographic, clinical and laboratory data Study assessments took place during follow-up clinic visits. We collected the following demographic and clinical data: age, sex, race, ethnicity, weight, cause of heart failure, functional status and prescribed medications, including diuretics. Diagnoses of dilated and hypertrophic cardiomyopathies were based on the previously published echocardiographic criteria used for enrollment in the Pediatric Cardiomyopathy Registry [22] . Functional status was established by the New York Heart Association (NYHA) class for children older than 5 years and by the Ross classification for younger children [23] . The Ross classification assigns children to four different classes of heart failure severity based on feeding history, growth parameters and physical findings.
Blood samples were collected during routine blood draws to avoid additional venipuncture. The samples were then centrifuged, aliquoted and stored at −80°C until batched assays were performed. Plasma c-terminal FGF23 levels were measured by an enzyme-linked immunosorbent assay [ELISA; Immutopics, San Clemente, CA; coefficient of variance (CV) <5 %], and plasma intact parathyroid hormone (PTH) was measured using a chemiluminescent immunoassay (Roche Diagnostics, Indianapolis, IN; CV <3 %). Serum NT-proBNP was measured using the Elecsys 2010 System (Roche Diagnostics). The clinical laboratory using standard procedures performed routine laboratory testing of blood, including renal function. Estimated glomerular filtration rate (eGFR; in ml/min/1.73 m 2 ) was determined using an established formula of eGFR=0.41 × height (cm)/serum creatinine (mg/dl) [24] . Fractional excretion of mineral [phosphate (FePi); calcium (FeCa)] was calculated from spot urine collections as: (urine mineral × serum creatinine × 100)/ (serum mineral × urine creatinine). The laboratory's reference ranges were 2.5-4.5 mg/dl for serum phosphate, 8.4-10.2 mg/dl for serum calcium and 15-65 pg/ml for PTH. In accordance with previously published data [25] , levels of NT-proBNP ≥150 pg/ml in infants younger than 1 year, or ≥100 pg/mL in children aged ≥1 year, were considered abnormal. Due to limited volume of stored plasma from healthy controls, these samples were only assayed for FGF23 and PTH.
Echocardiography
All pediatric heart failure patients underwent transthoracic echocardiography using a commercially available system (Acuson Sequoia Ultrasound System C512; Acuson, Mountain View, CA). The images were recorded digitally and subsequently reviewed by two experienced pediatric cardiologists unaware of the serum tests results. M-mode tracing was obtained in the parasternal short-axis view at the level of the papillary muscles of the LV, and LV end-systolic and end-diastolic diameters were measured. To obtain normative values for echocardiographic measures, we used previously published data from 580 healthy patients aged 0-40 years [26, 27] . Using methods described elsewhere [28] , we used the estimated means and standard deviations from regression equations to calculate Z scores for LV end-systolic diameter, LV end-diastolic diameter, septal wall thicknesses, LV posterior wall thicknesses, and LV mass relative to body surface area and Z scores for LV fractional shortening relative to age in our sample. LV ejection fraction was calculated in the apical two-and four-chamber views using Simpson's apical biplane method, as recommended by the American Society of Echocardiography [29] . LV mass was calculated by M-mode using the Devereux formula [30] .
Statistical analysis
Demographic, clinical and laboratory values are reported as descriptive statistics. When possible, we compared values between patients and controls using t tests or Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. Spearman correlation coefficients were used to assess correlations. Linear regression modeling was performed to adjust for eGFR as a potential confounder. The distributions of FGF23, PTH and NT-proBNP were rightskewed, requiring natural log (ln)-transformation. Since the etiology of heart failure was heterogeneous in our pediatric patients, we restricted analyses of associations of FGF23 with echocardiographic measures only to children with dilated cardiomyopathy. Analyses were performed with the SAS ver. 9.2 statistical software program (SAS Institute, Cary, NC). All statistical tests were two-sided, and P values of <0.05 were considered to be significant.
Results
Patient characteristics
We studied 20 patients (mean age 12±6 years) with heart failure and 17 healthy controls (mean age 13±3 years) ( Table 1) . Among the patients, 11 had dilated cardiomyopathy; the remaining etiologies included congenital heart disease 
(single ventricle, n=2; tetralogy of Fallot, n=1; dextrotransposition of great arteries, n=1), hypertrophic cardiomyopathy (n=3), failing heart transplant (n=1), and pulmonary hypertension (n=1). Loop diuretics were prescribed to nine patients (45%), and eight patients (40 %) were NYHA or Ross functional class II or higher (Table 1) . Aside for lower frequency of girls in the diuretics-treated group, there were no significant differences in demographic and clinical characteristics between the two patient groups (Table 2) . Per the matched study design, the distribution of demographic characteristics, including age, sex, race, and ethnicity, did not vary significantly between the patients and controls ( Table 1) .
Associations between baseline factors and FGF23 levels
There was no significant association between age, gender, race or ethnicity and FGF23 levels in our study population. Mean serum phosphate levels in the patients were within the reported reference range for healthy children [31] , and median PTH levels were in the normal range in patients and controls (Table 1 ). In contrast, the median FGF23 level was 110.9 [interquartile range (IQR) 78.4-187.1] RU/ml, which is markedly higher than the median levels of 30-70 RU/ml reported in other studies of healthy children of comparable age [32, 33] . Among our patients, FGF23 levels were almost double that of the controls (110.9 vs. 66.4 RU/ml, respectively; P=0.03) ( (Fig. 1) . Among patients, FGF23 and NT-proBNP levels were directly correlated (r=0.47, P=0.04; Fig. 2 (Fig. 3) . Both the association with NT-proBNP and with functional class was independent of eGFR, which was not a significant predictor of FGF23 concentrations (Table 3 ). In contrast, PTH was associated with FGF23 levels (r=0.670, P=0.001) but not with serum phosphate (r=0.40, P=0.08). 
Correlations between FGF23 levels and echocardiographic measurements
The echocardiographic findings in the 11 patients with dilated cardiomyopathy, of whom three were assessed to be in a functional class of II or greater and four were on diuretics, are presented in Table 4 . In these patients, there was also no significant association between eGFR and FGF23 levels (r=−0.37, P = 0.26), but FGF23 levels correlated with echocardiographic indicators of abnormal cardiac structure (Table 5 ). Higher FGF23 levels correlated with a greater LV end-diastolic diameter (r=0.63, P=0.04) and with a larger LV mass, although the latter association did not reach significance (r=0.61, P = 0.06). Levels of NT-proBNP were inversely correlated with LV ejection fraction (r=−0.61, P=0.046), but not with the LV end-diastolic diameter (r=0.57, P=0.07; Table 5 ). In contrast, eGFR, serum phosphate and PTH levels were not significantly associated with any of the echocardiographic measures (data not shown). Finally, in a model that included both FGF23 and eGFR, neither variable was a significant predictor of LV end-diastolic diameter.
Discussion
The first new finding of our study is the demonstration of nearly twofold higher FGF23 levels in the pediatric heart failure population compared to healthy controls. We further show a significant relationship between FGF23, heart failure symptom severity and echocardiographic measures of abnormal cardiac structure. Additionally, FGF23 levels correlated directly with NT-pro-BNP levels. Patients with more symptomatic heart failure, as evidenced by treatment with diuretics and advanced heart failure dysfunctional class, had higher FGF23 levels. These data suggest that FGF23 levels might predict clinical status in heart failure. Elevated FGF23 in this setting might also indicate that hemodynamic consequences Fig. 1 Median fibroblast growth factor 23 (FGF23) levels in healthy children and children with heart failure, treated with diuretics (Diuretics +) and without diruretics (Diuretics −). Fig. 2 Correlation between N-terminal prohormone brain natriuretic peptide (NT-proBNP) and fibroblast growth factor 23 (FGF23) levels in children with heart failure. FGF23 and NT-proBNP levels were directly correlated in children with heart failure (r=0.47, P=0.04) of heart failure led to increased FGF23 prior to occult changes in kidney function. Further studies are needed to investigate the role of FGF23 in heart failure. Our findings suggest that heart failure may be another common medical condition in which levels of FGF23 are elevated. Further, correlates of FGF23 levels in this population may differ from those in the healthy pediatric population [33] , as our data on the univariate FGF23 predictors in the two study groups seem to indicate. While cross-sectional design and residual confounding by kidney function limit our inferences, prior experimental and longitudinal observations support the possibility of a link between FGF23 levels and cardiac structure [14, 19, 34] . Higher FGF23 levels associate with greater risk of prevalent and incident LV hypertrophy [14, 19, 34] , and FGF23 exerts hypertrophic effects on the myocardium in animal models [19] .
FGF23 may also have detrimental effects on the vasculature, although the data on this mechanism of systemic FGF23 toxicity are less consistent. A large study of patients with CKD stages 2-4 reported no significant association following multivariable adjustment between elevated FGF23 levels and calcification of the coronary arteries or thoracic aorta [35] . In contrast, FGF23 levels were significantly higher in children with
Kawasaki disease compared to healthy controls, and elevated levels independently predicted coronary artery damage [36] .
Among the pediatric heart failure patients, we observed that FGF23 levels correlated with NT-proBNP levels, a finding that is in agreement with the prior report of a similar relationship in the adult heart failure population [15, 16] . The consistent link between FGF23 and NT-proBNP, an established marker of cardiac wall stress [37, 38] , supports the hypothesis that FGF23 may have direct effects on the myocardium. This framework is also supported by recent observations in patients with kidney disease of associations of FGF23 with serum cardiac troponin levels [17, 18] , which are also released into circulation in settings of cardiac damage [39] .
In contrast to one adult study [15] , we found that FGF23 levels were significantly higher in those patients treated with diuretics and in those with higher NYHA or Ross functional class. These findings need to be confirmed in prospective studies. However, when evaluated in concert with a large body of evidence from longitudinal studies across multiple populations [8] [9] [10] , our data support the hypothesis that FGF23 measurements in the heart failure population might have prognostic utility.
The mechanisms for elevated FGF23 levels in heart failure are not known. One possibility is that impaired kidney function in the setting of hemodynamic compromise might lead to a rise in levels. While we did not detect an association between eGFR and FGF23 in our patients, eGFR may not accurately capture kidney function in heart failure. Given that greater diuresis might result in decreased renal perfusion, our observation of significantly higher FGF23 levels among patients treated with diuretics versus untreated patients supports the possibility of subtle loss of kidney function contributing to elevated FGF23 levels. Phosphate homeostasis is another factor that is important in FGF23 regulation. In our small study, we were not able to detect a significant association between serum phosphate and FGF23 levels, although prior large studies found a direct correlation between these two parameters [32, 40] . Alternatively, increased production in the bone or impaired post-translational modification and processing may result in elevated FGF23. Finally, the contribution of other organs, such as the heart itself, to circulating FGF23 levels remains undefined. Identifying which of these mechanisms of FGF23 elevation is important in heart failure will require further studies. Limitations of this study include the cross-sectional design, small sample size that impeded multivariate adjustment and limited availability of data in healthy controls. Additionally, the heterogeneity of patients by cause of heart failure further limited our ability to evaluate the relationship between FGF23 and echocardiographic measures. Despite frequency matching, the percentage of blacks in the control group was higher than in the patient group. Although this difference was not significant, and race was not a significant determinant of FGF23 levels in our study population, racial variability in FGF23 levels in children should be investigated further. Finally, we were not able to assess associations with vitamin D, which is known to influence FGF23 levels [41] and may also have effects on cardiac structure and function [42] .
The ability of FGF23 to predict future clinical events in adults has been consistently demonstrated [8] [9] [10] [11] . Our data now raise the possibility that FGF23 levels may also have a prognostic role in pediatric patients with heart failure and add justification to recent calls for novel biomarker development in this population [43] . Whether this prognostic utility of FGF23 measurements will be realized in this setting is unknown, and additional data are needed to confirm the direct effects of increased FGF23 on the myocardium and to establish its effects on other organs. These important questions warrant future investigation in prospective and experimental studies.
